Modigene to Present at the Roth 2007 New York Investor Conference

Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
Modigene to Present at the Roth 2007 New York Investor Conference
              - Presentation to be Webcast Live and Archived -

    VIENNA, Va., Aug. 29 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC
Bulletin Board: MODG) today announced that senior management will present
at the Roth 2007 New York Investor Conference on Thursday, September 6,
2007 at 3:00 pm EDT. The conference will be held at the Westin New York at
Times Square in New York City.
    Modigene CEO Abraham Havron and President Shai Novik will provide a
company overview and review of corporate developments.
    "As a relatively new public company, we look forward to this
opportunity to inform additional investors about our innovative technology
that has the potential to significantly extend the duration of virtually
any therapeutic protein drug," noted Dr. Havron. "We believe our product
pipeline has great clinical and commercial promise as a result of our
ability to increase the utility and convenience of a wide range of protein
therapeutics currently used by millions of patients each year."
    The Modigene presentation will be webcast live and can be accessed by
visiting http://www.wsw.com/webcast/roth13/modigene/. An archived version of the
presentation webcast will also be available following the conclusion of the
conference at the same address for approximately 90 days.
    For more information about the Roth 2007 New York Investor Conference,
visit http://www.roth.com/main/Page.aspx?PageID=7015.
    ABOUT MODIGENE
    Modigene Inc. (OTC Bulletin Board: MODG) is a biopharmaceutical company
applying its patented CTP technology to develop longer-acting, proprietary
versions of already approved therapeutic proteins that currently generate
billions of dollars in annual global sales. Modigene is currently
developing long-acting versions of human growth hormone, erythropoietin,
interferon beta, and GLP-1, which are in late preclinical development. For
more information on Modigene, please visit http://www.modigeneinc.com.
    Safe Harbor Statement: This press release contains forward-looking
statements, including statements regarding the results of current studies
and preclinical experiments and the effectiveness of Modigene's long-acting
protein programs and are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Investors are cautioned
that forward-looking statements involve risks and uncertainties that may
affect Modigene's business and prospects, including the risks that Modigene
may not succeed in developing any commercial products based upon its long-
acting protein technology, including any long-acting versions of human
growth hormone, erythropoietin, interferon beta or GLP-1; that the
long-acting products in development may fail, may not achieve the expected
results or effectiveness and/or may not generate data that would support
the approval or marketing of these products for the indications being
studied or for other indications; that ongoing studies may not continue to
show substantial or any activity; and other risks and uncertainties that
may cause results to differ materially from those set forth in the
forward-looking statements. The development of any products using the CTP
platform technology could also be affected by a number of other factors,
including unexpected safety, efficacy or manufacturing issues, additional
time requirements for data analyses and decision making, the impact of
pharmaceutical industry regulation, the impact of competitive products and
pricing and the impact of patents and other proprietary rights held by
competitors and other third parties. In addition to the risk factors set
forth above, investors should consider the economic, competitive,
governmental, technological and other factors discussed in Modigene's
filings with the Securities and Exchange Commission.
    MODIGENE CONTACT:              MEDIA CONTACT:
    Shai Novik, President          Barbara Lindheim
    Modigene Inc.                  GendeLLindheim BioCom Partners
    Tel: +1 866 644-7811           +1 212 918-4650
    Email: shai@modigeneinc.com
SOURCE Modigene Inc.
http://www.modigeneinc.com
CONTACT:
Shai Novik, President of Modigene Inc.,
+1-866-644-7811, shai@modigeneinc.com; or Barbara Lindheim of
GendeLLindheim BioCom Partners, +1-212-918-4650